Szilard Voros, MD, FACC, FSCCT, FAHA, Founder & CEO, Global Genomics Group (G3), discusses the immense obstacles to efficiently diagnosing cardiovascular disease. G3’s extensive research has worked towards developing a blood test with a quick turnaround time that will identify a negative test to 95% accuracy. Furthermore, new imaging techniques under development will allow physicians to observe the vessel walls where plaque resides.

Resources & References:

http://www.clinicaltrials.gov/ct2/show/NCT01738828?lead=Global+Genomics+Group&rank=1